HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Ellen Miles Selected Research

Immunotherapy

4/2018Management of newly diagnosed high-risk and intermediate-risk follicular lymphoma with 90 Y ibritumomab tiuxetan in a phase II study.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Ellen Miles Research Topics

Disease

1Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
12/2021
1Follicular Lymphoma (Lymphoma, Small Cleaved Cell, Follicular)
04/2018
1Rubella (German Measles)
04/2018
1Thrombocytopenia (Thrombopenia)
04/2018
1Neutropenia
04/2018

Drug/Important Bio-Agent (IBA)

1Antineutrophil Cytoplasmic Antibodies (ANCA)IBA
12/2021
1ibritumomab tiuxetan (Zevalin)FDA Link
04/2018
1Immunoglobulins (Immunoglobulin)IBA
04/2018

Therapy/Procedure

1Immunotherapy
04/2018